Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 3;28(6):1167–1177. doi: 10.1038/s41591-022-01829-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a, Kaplan–Meier curves for OS stratified by frequencies of circulating CD38⁺ EM CD8 T cells by flow cytometry, pre-treatment (C1D1) above and below the median frequency. b, Heat map of relative median fluorescence intensity of markers on CD38⁺ EM CD8 T cells from pre-treatment PBMC samples across patients in the nivo/chemo arm. c, Frequencies of CD38⁺ EM CD8 T cells pre-treatment (C1D1) and on-treatment PBMC samples (C1D15, C2D1 and C4D1), grouped by patient survival status at 1 year. d, Kaplan–Meier curves for OS stratified by frequencies of circulating PD-1⁺CD39⁺ EM1 CD4 T cells. e, Heat map of relative median fluorescence intensity of markers present on PD-1⁺CD39⁺ EM1 CD4 T cell population from pre-treatment PBMC samples across patients in the nivo/chemo arm. f, Frequencies of PD-1⁺CD39⁺ EM1 CD4 T cells in pre-treatment (C1D1) and on-treatment PBMC samples (C1D15, C2D1 and C4D1), grouped by patient survival status at 1 year. g, Kaplan–Meier curves for OS stratified by frequencies of circulating T_fh (CXCR5⁺PD-1⁺CD4⁺) cells. h, Heat map of relative median fluorescence intensity of markers present on pre-treatment T_fh cells across all patients from pre-treatment PBMC samples in the nivo/chemo arm. i, Frequencies of T_fh cells pre-treatment and on-treatment (C1D15, C2D1 and C4D1). For all cell populations shown, frequencies are out of parent population. Box plots show median and quartiles, and whiskers depict 95% CI. Individual patient values are shown in thin lines. Color depicts survival status at 1 year. P values for time series represent two-sided Wilcoxon signed-rank tests between time points, illustrating changes on-treatment (c) or survival groups at each time point (f and i). On Kaplan–Meier curves, median values were determined using all data across the three arms; P values are from a log-rank test between groups; and shaded regions illustrate 95% CI. Sample sizes for cell populations are shown (c, f and i): n = 26, 21, 25 and 19 biologically independent samples at C1D1, C1D15, C2D1 and C4D1, respectively.